Santa Clara Magazine is published in print for alumni and friends of the University. It is updated weekly on the web.
Thomas S. Templeman ’81 has joined Graybug Vision as Chief Operating Officer. The company is a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma. A seasoned pharmaceutical executive with more than 25 years of cross-functional experience, Dr. Templeman joins Graybug Vision from Medivation (acquired by Pfizer in late 2016), where he was Senior Vice President Pharmaceutical Operations and Quality. In that role, he was responsible for early and late-stage pharmaceutical development, operations and quality including early developmental candidates, clinical developmental candidates and marketed products. As a member of the Medivation Executive Committee, Dr. Templeman was responsible for developing and implementing company vision and strategy.
Thomas S. Templeman, PhD, said, "There is a dramatic increase in eye diseases due to our aging population, and an increased need for new and more effective treatments. Graybug Vision’s novel delivery technology, to create injectable, long-acting products to deliver single or multiple drugs for up to one year in the eye, significantly reduces the treatment burden on patients and physicians. I am excited to join the management team with our efforts to deliver innovative care to patients."
Dr. Templeman began his career as a research and development scientist and over the past two decades has held management positions at, among others: Ortho Diagnostic Products and Centocor Biologics; Liquidia Technologies, where he was Senior Vice President, Integrated Supply Chain; and at Hospira, where he was Vice President, Manufacturing, Science & Technology.